DxTerity

Executive Summary

DxTerity is a private genomics company pioneering RNA-based immune system profiling to uncover the root causes of autoimmune diseases. Unlike static DNA testing, RNA testing reflects dynamic changes due to environment and disease state, offering a more complete view of patient status. Founded in 2013 and headquartered in Los Angeles, the company aims to improve diagnosis and treatment monitoring for autoimmune conditions. While financials, stage, and pipeline details are not publicly available, DxTerity's innovative approach positions it in a growing precision medicine market. The company may seek partnerships or funding to advance its platform, but lack of disclosed data limits near-term visibility.

Upcoming Catalysts (preview)

• TBDClinical study validation of RNA autoimmune panel40% success
• TBDStrategic partnership with a pharmaceutical company30% success
• TBDLaunch of commercial diagnostic test for lupus or rheumatoid arthritis20% success